Kevin Xu has moved "all in" on Hims & Hers Health ($HIMS), purchasing 2,316 shares at an average price of $26.72 following a 1,000-share exit from Iris Energy ($IREN) at $61.85. The bullish thesis for $HIMS cites high consumer demand for peptides and a potential short squeeze due to a 34% short interest ahead of earnings on May 11. While the position is currently up over 10% at a price of $29.48, the analyst notes risks including margin compression from distributing branded Wegovy and an ongoing lawsuit from Novo Nordisk.